Riboxin-Darnitsa (inosine) coated tablets 200 mg. №50

Description

Riboxin-Darnitsa (inosine) coated tablets 200 mg. №50

Composition

active ingredient: inosine;

1 tablet contains riboxin (inosine) 200 mg;

excipients: potato starch, crystalline sugar, methylcellulose, stearic acid, polysorbate 80, tropeolin 0, titanium dioxide (E 171).

Dosage form

Coated tablets.

Basic physical and chemical properties: yellow coated tablets with a biconvex surface. The cross section shows two layers.

Pharmacological group

Cardiac drugs.
ATX code C01E B.

Pharmacological properties

Riboxin-Darnitsa belongs to the group of cardiological agents.
Due to its properties, the drug improves metabolic processes in the myocardium, increases the strength of heart contractions and the activity of a number of enzymes of the Krebs cycle, promotes more complete relaxation of the myocardium in diastole. Improves blood supply to tissues and coronary blood supply, activates tissue regeneration (in particular myocardium, intestinal mucosa and stomach).

Indications for use

Riboxin-Darnitsa tablets is used as part of complex treatment for coronary heart disease (condition after myocardial infarction, angina pectoris), cardiac arrhythmias, intoxication with cardiac glycoside preparations, treatment of cardiomyopathies of various origins, myocardial dystrophies (due to heavy physical exertion, infectious and endocrine genesis), myocarditis; liver diseases (hepatitis, cirrhosis of the liver, fatty degeneration of the liver); urocoproporphyria.

Contraindications

The drug Riboxin-Darnitsa is contraindicated for use in the presence of diseases such as gout, hyperuricemia and renal failure. Also, the drug is not used by persons with increased susceptibility to the components of the drug and in childhood.

Pregnancy and breastfeeding period

The use of the drug Riboxin during pregnancy and lactation is contraindicated.

Mode of application

The drug Riboxin-Darnitsa tablets is used before meals, without chewing and drinking plenty of water.
The recommended dose for adult patients is 600-2400 mg per day, a more accurate dosage is set by the doctor for each patient individually.
At the beginning of treatment, 1 tablet is prescribed 3-4 times a day (600-800 mg), with good tolerance, the dose is gradually increased over 2-3 days, 2 tablets 3 times a day (1200 mg), if there is a need for 4 tablets 3 times a day (2400 mg).
The duration of therapy is 1-3 months.

Overdose

An overdose of Riboxin-Darnitsa tablets is accompanied by the following symptoms: allergic reactions, increased manifestations of side reactions. In case of drug intoxication, symptomatic treatment is used.

Adverse reactions

The use of the drug Riboxin-Darnitsa tablets very rarely causes side effects, but sometimes it is possible: itching, rash, skin flushing, an increase in the concentration of uric acid in the blood and tachycardia. With prolonged use or in high dosages, exacerbation of gout may occur.